Results 11 to 20 of about 25,411 (262)
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
Vascular Health and Risk Management, 2017 Juan Carlos Yugar-Toledo,1 Rodrigo Modolo,2 Ana Paula de Faria,2 Heitor Moreno2 1São José do Rio Preto Medicine School – FAMERP, São José do Rio Preto, 2School of Medical Sciences, University of Campinas (UNICAMP ...
Yugar-Toledo JC +3 more
doaj +4 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Mineralocorticoid receptor antagonists promote renal immunosenescence. [PDF]
Int Urol NephrolAbstract Chronic kidney disease (CKD) is often associated with chronic inflammation, influenced by the activation of mineralocorticoid receptors (MR). This review focuses on changes in immune cells and explores the important role that MR antagonists (MRAs), especially the new nonsteroidal MRA, finerenone, play in alleviating renal and
Wang QR, Yang Y.
europepmc +3 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources
Mineralocorticoid receptor antagonists in cardiovascular translational biology. [PDF]
Cardiovasc Endocrinol Metab, 2023 This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes.
Chilton RJ, Silva-Cardoso J.
europepmc +3 more sources
Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis. [PDF]
, 2016 Aim We assessed the effectiveness of fourth-line mineralocorticoid receptor antagonists in comparison with other fourth-line anti-hypertensive agents in resistant hypertension.
Douglas, Ian J +6 more
core +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Guideline‐recommended disease‐modifying pharmacological therapies for heart failure (HF) with reduced ejection fraction are underutilized, particularly among elderly patients.
Caroline H. Garred +11 more
doaj +1 more source
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. [PDF]
PLoS ONE, 2014 It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties, because these drugs reduce mortality in patients with heart failure.
T N A van den Berg +5 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj +1 more source